Company description
Denali Therapeutics Inc. (DNLI) is a biotechnology company that focuses on the development and commercialization of therapies for neurodegenerative diseases. Founded in 2013, the company is headquartered in South San Francisco, California and has a global reach with offices in Japan and Switzerland. Their mission is to discover new and effective treatments for conditions such as Alzheimer's, Parkinson's, and Amyotrophic lateral sclerosis (ALS) by targeting the root causes of these diseases. Denali utilizes their proprietary technology platform, called "Enginuity," to create novel treatments that penetrate the brain and target specific disease-causing proteins. This approach allows them to develop therapies that can potentially slow down or stop disease progression, rather than just treating the symptoms. The company has a strong pipeline of drug candidates in various stages of development, with a focus on Parkinson's disease as their lead indication. In addition to their internal research and development efforts, Denali has numerous strategic partnerships with leading pharmaceutical companies such as Bristol-Myers Squibb, Takeda, and Sanofi. These collaborations allow the company to leverage their partners' expertise and resources to accelerate the development of their therapies. Since its inception, Denali has made significant progress in advancing their pipeline, with multiple drugs in clinical trials and a growing portfolio of potential treatments in preclinical development. They have also received recognition for their innovative approach and potential impact on patients' lives, including being named a "Fierce 15" company by